Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeuroPace, Inc.
Medtech Investment Outlook: In Health Care You Don’t Become A Unicorn Overnight
The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
VC Deals Analysis: Only Way Is Up As October Puts 2017 Ahead
Total takings from October's venture financing deals may not have been the highest, but the $295m raised by the 20-plus transactions last month is enough for 2017 to trump 2016 in total deal value – with more room to widen the gap.
- Implantable Devices
- Monitoring Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.